|
90 Companies |
|
65 Products |
|
65 Products |
|
50 Mechanisms of Action |
|
804 Trials |
|
63193 News |
|
| «12...691692693694695696697698699700701702703» |
- ||||| latanoprost / Generic mfg., travoprost ophthalmic / Generic mfg.
Enrollment change: Phase III Clinical Trial of TRAVATAN Z in Ocular Surface Health (clinicaltrials.gov) - Mar 29, 2012
P3, N=705, Completed, Sponsor: Alcon Research
N=1100 --> 705
- ||| latanoprost / Generic mfg., travoprost ophthalmic / Generic mfg.
Enrollment change: Effects of Travatan Z and Xalatan on Ocular Surface Health (clinicaltrials.gov) - Mar 29, 2012
P4, N=231, Completed, Sponsor: Alcon Research
N=1100 --> 705 N=110 --> 231
- Surgery: The Effect of Two Different Artificial Respiration Methods on the Intraocular Pressure During Surgery Under General Anesthesia (clinicaltrials.gov) - Mar 28, 2012
P=N/A, N=50, Not yet recruiting, Sponsor: Western Galilee Hospital-Nahariya
- Trial completion: PSOCT: Polarization Sensitive Retinal Tomography for Glaucoma Diagnosis (clinicaltrials.gov) - Mar 25, 2012
P=N/A, N=85, Completed, Sponsor: Courtney Frazier Swaney
N=110 --> 231 Recruiting --> Completed
- | New P2 trial: Safety and Performance of Miami InnFocus Drainage Implant (MIDI Arrow) Glaucoma Drainage Implant (clinicaltrials.gov) - Mar 22, 2012
P2, N=55, Active, not recruiting, Sponsor: InnFocus LLC
- | Lumigan (bimatoprost) / Senju, AbbVie
New P4 trial: Comparison between the effects on ocular pressure of Bimatoprost 0.01% and Timolol 0.5% during the day and night Confronto tra gli effetti sulla pressione degli occhi del Bimatoprost 0.01% e Timololo 0.5% di giorno e di notte (EUDRACT) - Mar 19, 2012
P4, N=40, Ongoing, Sponsor: IRCCS- FONDAZIONE G.B. BIETTI PER LO STUDIO E LA RICERCA IN OFTALMOLOGIA-ONLUS
- dorzolamide/timolol / Generic mfg.
Trial withdrawal: Xal-Cos: The Effects of Cosopt (clinicaltrials.gov) - Mar 14, 2012
P=N/A, N=0, Withdrawn, Sponsor: Meir Medical Center
Recruiting --> Completed Recruiting --> Withdrawn
- dorzolamide/timolol / Generic mfg.
Enrollment change: Xal-Cos: The Effects of Cosopt (clinicaltrials.gov) - Mar 14, 2012
P=N/A, N=0, Withdrawn, Sponsor: Meir Medical Center
Recruiting --> Withdrawn N=16 --> 0
- | Lucentis (ranibizumab) / Roche, Novartis
New P2 trial: The LIMO Study, Lucentis for Treatment of Uveitic Patients With Refractory Cystoid Macular Oedema (clinicaltrials.gov) - Mar 13, 2012
P2, N=20, Recruiting, Sponsor: Moorfields Eye Hospital NHS Foundation Trust
- |||||||||| New P2/3 trial: Shunt Tube Exposure Prevention Study (clinicaltrials.gov) - Mar 8, 2012
P2/3, N=96, Recruiting, Sponsor: Tissue Tech Inc.
- ||||| Lumigan (bimatoprost) / Senju, AbbVie
New P4 trial: Safety and Efficacy of LUMIGAN (clinicaltrials.gov) - Mar 6, 2012
P4, N=134, Completed, Sponsor: Allergan
- ||||| dorzolamide/timolol / Generic mfg., travoprost ophthalmic / Generic mfg.
Enrollment change: A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - Mar 1, 2012
P3, N=319, Completed, Sponsor: Alcon Research
N=16 --> 0 N=450 --> 319
- Enrollment change, Surgery: Ologen (OculusGen)-Phacotrabeculectomy Historical Control Study in India (clinicaltrials.gov) - Feb 28, 2012
P3, N=10, Completed, Sponsor: Pro Top & Mediking Company Limited
N=450 --> 319 N=20 --> 10
- Trial completion, Surgery: Ologen (OculusGen)-Phacotrabeculectomy Historical Control Study in India (clinicaltrials.gov) - Feb 28, 2012
P3, N=10, Completed, Sponsor: Pro Top & Mediking Company Limited
N=20 --> 10 Recruiting --> Completed
- |||||||||| New P3 trial, Surgery: Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON) (clinicaltrials.gov) - Feb 23, 2012
P3, N=800, Recruiting, Sponsor: Ivantis, Inc.
- ||| Trial completion: Nidek RS3000 Comparative Study (clinicaltrials.gov) - Feb 16, 2012
P=N/A, N=89, Completed, Sponsor: Nidek Co. LTD.
Recruiting --> Completed Recruiting --> Completed
- New P4 trial: Efficacy And Safety of Pneumatic Trabeculoplasty (clinicaltrials.gov) - Feb 15, 2012
P4, N=27, Completed, Sponsor: University of Cantanzaro
- ||||| Lumigan (bimatoprost) / Senju, AbbVie
New P4 trial: Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves (clinicaltrials.gov) - Feb 12, 2012
P4, N=150, Recruiting, Sponsor: Credit Valley EyeCare
- |||| evodenoson (ATL313) / AbbVie
Trial completion: Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - Feb 9, 2012
P1/2, N=147, Completed, Sponsor: Santen Inc.
Recruiting --> Completed Recruiting --> Completed
- travoprost ophthalmic / Generic mfg.
Trial withdrawal: Three Month Safety and Efficacy Study of TRAVATAN (clinicaltrials.gov) - Feb 8, 2012
P3, N=0, Withdrawn, Sponsor: Alcon Research
Recruiting --> Completed Not yet recruiting --> Withdrawn
- travoprost ophthalmic / Generic mfg.
Enrollment change: Three Month Safety and Efficacy Study of TRAVATAN (clinicaltrials.gov) - Feb 8, 2012
P3, N=0, Withdrawn, Sponsor: Alcon Research
Not yet recruiting --> Withdrawn N=720 --> 0
- | Rhopressa (netarsudil) / Aerie Pharma
Clinical: Study of AR-13324 in Patients With Elevated Intraocular Pressure (clinicaltrials.gov) - Feb 6, 2012
P2, N=85, Completed, Sponsor: Aerie Pharmaceuticals
- | dorzolamide/latanoprost (ALZ-1101) / Alleanza
New P2 trial: Efficacy and Safety of Topically Applied Medical Therapy for the Treatment of Pediatric Glaucoma (clinicaltrials.gov) - Feb 5, 2012
P2, N=68, Recruiting, Sponsor: Azienda Ospedaliera Spedali Civili di Brescia
- ||||| LX7101 / Lexicon Pharma
New P1/2 trial: Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - Feb 5, 2012
P1/2, N=63, Completed, Sponsor: Lexicon Pharmaceuticals
- |||| Lumigan (bimatoprost) / Senju, AbbVie
Trial completion: Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - Feb 5, 2012
P4, N=164, Completed, Sponsor: Allergan
N=720 --> 0 Active, not recruiting --> Completed
- ||||||| Trial completion, Combination therapy, Surgery: A Study of the Trabecular Micro-bypass Stent in Combination With Cataract Surgery in Subjects With Open Angle Glaucoma (clinicaltrials.gov) - Feb 4, 2012
P3, N=240, Completed, Sponsor: Glaukos Corporation
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Lumigan (bimatoprost) / Senju, AbbVie
New P4 trial: A Safety and Efficacy Study of ALPHAGAN (clinicaltrials.gov) - Jan 31, 2012
P4, N=137, Completed, Sponsor: Allergan
- ||| Enrollment change: DuoTrav (clinicaltrials.gov) - Jan 30, 2012
P4, N=128, Completed, Sponsor: Alcon Research
Active, not recruiting --> Completed N=2000 --> 128
- ||| Combigan (brimonidine tartrate/timolol maleate) / AbbVie
Trial completion: Safety and Efficacy of Brimonidine Tartrate/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension (clinicaltrials.gov) - Jan 30, 2012
P=N/A, N=238, Completed, Sponsor: Allergan
N=2000 --> 128 Recruiting --> Completed
- ||||| timolol maleate ophthalmic solution / Generic mfg.
New P1/2 trial: Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension (clinicaltrials.gov) - Jan 25, 2012
P1/2, N=180, Active, not recruiting, Sponsor: Altheos, Inc.
- | Combigan (brimonidine tartrate/timolol maleate) / AbbVie
New P4 trial, Combination therapy: Assessing the Efficacy and Tolerability of AZARGA (clinicaltrials.gov) - Jan 23, 2012
P4, N=50, Completed, Sponsor: Alcon Research
- ||||| New P4 trial: One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma Subjects (clinicaltrials.gov) - Jan 23, 2012
P4, N=120, Recruiting, Sponsor: Glaukos Corporation
- Enrollment open: Evaluation of Safety and Efficacy of Glaucoma Shunt (Aurolab Artificial Drainage Implant) in Refractory Glaucoma (clinicaltrials.gov) - Jan 23, 2012
P4, N=30, Recruiting, Sponsor: Aurolab
Recruiting --> Completed Not yet recruiting --> Recruiting
- Trial termination: Continuous Intraocular Pressure (IOP) Monitoring in Pigmentary Dispersion Syndrome and Pigmentary Glaucoma Patients (clinicaltrials.gov) - Jan 22, 2012
P=N/A, N=15, Terminated, Sponsor: Sensimed AG
Active, not recruiting --> Terminated; Law agreement between Triggerfish signal and GAT IOP during both sessions. However, an increase in the Triggerfish signal was observed during jogging phase.
- || Clinical: Open-Angle Glaucoma Subjects With One Prior Trabeculectomy Treated Concurrently With One Suprachoroidal Stent and Two Trabecular Micro-bypass Stents (clinicaltrials.gov) - Jan 22, 2012
P=N/A, N=80, Recruiting, Sponsor: Glaukos Corporation
However, an increase in the Triggerfish signal was observed during jogging phase. N=40 --> 80
- ||| travoprost ophthalmic / Generic mfg.
Clinical: Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost (clinicaltrials.gov) - Jan 22, 2012
P4, N=200, Recruiting, Sponsor: Glaukos Corporation
N=40 --> 80 N=100 --> 200
- ||| Clinical: A Prospective Evaluation of Open-Angle Glaucoma Subjects on Two Topical Hypotensive Medications Treated With One Suprachoroidal Stent (clinicaltrials.gov) - Jan 22, 2012
P4, N=80, Recruiting, Sponsor: Glaukos Corporation
N=100 --> 200 N=40 --> 80
- |||||| Surgery: Multicenter Study Using Glaukos (clinicaltrials.gov) - Jan 22, 2012
P3, N=1200, Recruiting, Sponsor: Glaukos Corporation
N=40 --> 80 Not yet recruiting --> Recruiting
- |||||| Surgery: Multicenter Investigation of the Glaukos (clinicaltrials.gov) - Jan 22, 2012
P3, N=200, Recruiting, Sponsor: Glaukos Corporation
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Clinical: A Prospective Evaluation of Open-Angle Glaucoma Subjects on Two Topical Hypotensive Medications Treated With One Suprachoroidal Stent (clinicaltrials.gov) - Jan 22, 2012
P4, N=80, Recruiting, Sponsor: Glaukos Corporation
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- ||| Enrollment closed, Surgery: Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Randomized to Treatment With One or Two Trabecular Micro-bypass Stents in Conjunction With Cataract Surgery (clinicaltrials.gov) - Jan 22, 2012
P4, N=80, Active, not recruiting, Sponsor: Glaukos Corporation
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Enrollment closed: Open-angle Glaucoma Subjects on One Ocular Hypotensive Medication Randomized to Treatment With Two Trabecular Micro-bypass Stents or Selective Laser Trabeculoplasty (clinicaltrials.gov) - Jan 22, 2012
P4, N=80, Active, not recruiting, Sponsor: Glaukos Corporation
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| travoprost ophthalmic / Generic mfg.
Clinical: Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost (clinicaltrials.gov) - Jan 22, 2012
P4, N=100, Active, not recruiting, Sponsor: Glaukos Corporation
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Enrollment closed: Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-angle Glaucoma (POAG) (clinicaltrials.gov) - Jan 22, 2012
P4, N=200, Active, not recruiting, Sponsor: Glaukos Corporation
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Combigan (brimonidine tartrate/timolol maleate) / AbbVie
New P4 trial, Combination therapy: Assessing the Efficacy and Tolerability of AZARGA (clinicaltrials.gov) - Jan 19, 2012
P4, N=9, Terminated, Sponsor: Alcon Research
- timolol maleate ophthalmic solution / Generic mfg., travoprost ophthalmic / Generic mfg.
New P4 trial: Efficacy of Changing to DuoTrav (clinicaltrials.gov) - Jan 19, 2012
P4, N=37, Terminated, Sponsor: Alcon Research
- ||| Combigan (brimonidine tartrate/timolol maleate) / AbbVie
Trial initiation date: Efficacy and Tolerability of AZARGA (clinicaltrials.gov) - Jan 18, 2012
P4, N=54, Completed, Sponsor: Alcon Research
Recruiting --> Active, not recruiting Initiation date: Jan 2011 --> Oct 2011
- |||| latanoprost / Generic mfg., timolol maleate ophthalmic solution / Generic mfg.
Trial completion, Combination therapy: AR-12286 in Combination With Latanoprost (clinicaltrials.gov) - Jan 18, 2012
P2, N=66, Completed, Sponsor: Aerie Pharmaceuticals
Initiation date: Jan 2011 --> Oct 2011 Active, not recruiting --> Completed
- Trial withdrawal: Safety and Efficacy Study of DuoTrav APS Versus DuoTrav (clinicaltrials.gov) - Jan 16, 2012
P3, N=0, Withdrawn, Sponsor: Alcon Research
Active, not recruiting --> Completed Terminated --> Withdrawn
- Enrollment change: Safety and Efficacy Study of DuoTrav APS Versus DuoTrav (clinicaltrials.gov) - Jan 16, 2012
P3, N=0, Withdrawn, Sponsor: Alcon Research
Terminated --> Withdrawn N=330 --> 0